BioSpace News Archive

Miri today announces its lineup of experts infusing the knowledge provided to users.

Syneos Health® has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients.

Inozyme Pharma, Inc. today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Avantor, Inc. today announced that Benoit Gourdier will join the company as EVP, Biopharma Production on October 2, 2023.

Axial Therapeutics today announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead product candidate, AB-2004, a first-in-class oral gut-targeted small molecule therapeutic designed to treat irritability associated with autism.

Inspire Medical Systems, Inc. announced key events at the International Surgical Sleep Society and American Academy of Otolaryngology meetings in Nashville, TN, September 29 through October 4.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today announced that it has completed patient enrollment in its Phase 1 clinical trial (NCT03978689) evaluating CUE-101.

Motus GI Holdings, Inc., a medical technology company focused on improving endoscopic outcomes and experiences, announced that it has submitted a special 510 to the U.S. Food and Drug Administration for market clearance of its Pure-Vu Gen 4 Gastro and Colon.

Armata Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2a portion of the Company’s diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of the study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion.

Satio is pleased to announce a $3.5 million Small Business Innovation Research (SBIR) contract awarded by the Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services.